Russian Heart Failure Journal 2008year Role of adipose tissue in the pathogenesis of chronic heart failure


To access this material please log in or register

Register Authorize
2008/

Role of adipose tissue in the pathogenesis of chronic heart failure

Arutyunov G.P., Shavgulidze K.B., Bylova N.A.

Keywords:

DOI:

Adipose tissue is a peculiar kind of connective tissue with special features. Two types of adipose tissue are isolated, white and brown ones which differ by their distribution in the body, adipocyte structure and degree of blood supply. Adipose tissue is a source of hormones (leptin, adiponectin), cytokines (TNF-α, IL-1, IL-6), prostaglandins and growth factors, levels of which change depending on the amount of adipose tissue. Epidemiological studies have shown that body weight and mortality are interrelated: mortality sharply increases at body weight of 70 % of ideal. Body wasting is a condition characterized by depletion of fat stores of the body. Cardiac cachexia is a kind of wasting which develops at terminal stages of CHF resulting in hormonal changes not typical for other types of cachexia (neurogenic anorexia; oncological cachexia). At present time some drugs are described, which influence properties of adipose tissue through adipocyte receptors, PPARγ or β3‑adrenoceptors; however recommendations on correction of the cardiac cachexia syndrome are not available.
    1.    Быков В. Л. Цитология и общая гистология: Функциональная морфология клеток и тканей человека: Учеб, для студ. мед. ин‑тов. – СПб.: Сотис. 2001. – 520 с.
    2.    Зайчик А. Ш., Чурилов Л. П. Основы общей патологии: Основы патохимии: Для мед. вузов. – СПб.: ЭЛБИ‑СПб, 2000. – 688 с.
    3.    Rosen E D, Spiegelman B M. Molecular regulation of adipogenesis. Annu Rev Cell Dev Biol. 2000;16:145–171.
    4.    Mori Y, Itoh Y, Tajima N. Angiotensin II Receptor Blockers Downsize Adipocytes in Spontaneously Type 2 Diabetic Rats With Visceral Fat Obesity. Am J Hypertens. 2007;20 (4):431–436.
    5.    Giordano A, Centemeri C, Zingaretti MC, Cinti S. Sibutramine-dependent brown fat activation in rats: an immunohistochemical study. Int J Obes Relat Metab Disord. 2002;26 (3):354–360.
    6.    Larsen TM, Toubro S, van Baak MA et al. Effect of a 28‑d treatment with L-796568, a novel beta (3)-adrenergic receptor agonist, on energy expenditure and body composition in obese men. Am J Clin Nutr. 2002;76 (4):780–788.
    7.    Maffei A, Vecchione C, Aretini A et al. Characterization of nitric oxide release by nebivolol and its metabolites. Am J Hypertens. 2006;19 (6):579–586.
    8.    Dessy C, Saliez J, Ghisdal P et al. Endothelial beta3‑adrenoreceptors mediate nitric oxide-dependent vasorelaxation of coronary microvessels in response to the third-generation beta-blocker nebivolol. Circulation 2005;112 (8):1198–1205.
    9.    Araki K, Masaki T, Katsuragi I et al. Telmisartan Prevents Obesity and Increases the Expression of Uncoupling Protein 1 in Diet-Induced Obese Mice. Hypertension. 2006;48 (1):51–57.
    10.    Cannon B, Nedergard J. Brown Adipose Tissue: Function and Physiological Significance. Physiology Review. 2004; 84 (1):277–359.
    11.    Дедов И. И., Мельниченко Г. А., Романцова Т. И. Патогенетические аспекты ожирения. Ожирение и метаболизм. 2004;1:3–9.
    12.    Sierra-Johnson J, Romero-Corral A, Lopez-Jimenez F et al. Relation of increased leptin concentrations to history of myocardial infarction and stroke in the United States population. Am J Cardiol. 2007;100 (2):234–239.
    13.    Бутрова С. А., Дзгоева Ф. Х. Висцеральное ожирение – ключевое звено метаболического синдрома. Ожирение и метаболизм. 2004;1:10–16.
    14.    Unger R H. Lipotoxic diseases. Annu Rev Med. 2002;53:319–336.
    15.    Залесский В. Н. Великая Н. В. Апоптоз адипоцитов и механизмы лептинзависимой регуляции ожирения и избыточной массы тела (состояние, проблемы, перспективы). Проблемы харчування. 2004;3 (4):26–33.
    16.    Guzik TJ, Mangalat D, Korbut R et al. Adipocytokines – novel link between inflammation and vascular function? J Physiol Pharmacol. 2006;57 (4):505–528.
    17.    Fasshauer M, Paschke R. Regulation of adipocytokines and insulin resistance. Diabetologia. 2003;46 (12):1594–1603.
    18.    Tilg H, Moschen AR. Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nat Rev Immunol. 2006;6 (10):772–783.
    19.    Viikari LA, Huupponen RK, Viikari JS. Relationship between Leptin and C-Reactive Protein inYoung Finnish Adults. J Clin Endocrinol Metab. 2007;92 (12):4753–4758.
    20.    Söderberg S, Stegmayr B, Stenlund H et al. Leptin, but not adiponectin, predicts stroke in males. J Intern Med. 2004 Aug;256 (2):128–136.
    21.    Wolk R, Berger P, Lennon RJ et al. Plasma leptin and prognosis in patients with established coronary atherosclerosis. J Am Coll Cardiol. 2004;44 (9):1819–1824.
    22.    Araki K, Masaki T, Katsuragi I et al. Telmisartan prevents obesity and increases the expression of uncoupling protein 1 in diet-induced obese mice. Hypertension. 2006;48 (1):51–57.
    23.    Kintscher U. Does adiponectin resistance exist in chronic heart failure? Eur Heart J. 2007;28 (14):1676–1677.
    24.    Alberti L, Gilardini L, Girola A et al. Adiponectin receptors gene expression in lymphocytes of obese and anorexic patients. Diabetes Obes Metab. 2007;9 (3):344–349.
    25.    Dekker JM, Funahashi T, Nijpels G et al. Prognostic value of adiponectin for cardiovascular disease and mortality. J Clin Endocrinol Metab. 2008 Jan 22; [Epub ahead of print].
    26.    Bluher M, Williams C J, Kloting N et al. Gene expression of adiponectin receptors in human visceral and subcutaneous adipose tissue is related to insulin resistance and metabolic parameters and is altered in response to physical training. Diabetes Care. 2007 Dec;30 (12):3110–3115.
    27.    Perseghin G, Lattuada G, De Cobelli F et al. Serum Retinol-Binding Protein-4, Leptin, and Adiponectin Concentrations Are Related to Ectopic Fat Accumulation. J Clin Endocrinol Metab. 2007;92 (12):4883–4888.
    28.    Marso SP, Mehta SK, Frutkin A et al. Low Adiponectin Levels are Associated with Atherogenic Dyslipidemia and Lipid-Rich Plaque in Non-Diabetic Coronary Arteries. Diabetes Care. 2008 Feb 5 [Epub ahead of print].
    29.    Hopkins TA, Ouchi N, Shibata R, Walsh K. Adiponectin actions in the cardiovascular system. Cardiovasc Res. 2007;74 (1):11–18.
    30.    Zeng Q, Fu L, Takekoshi K et al. Effects of short-term exercise on adiponectin and adiponectin receptor levels in rats. Journal of atherosclerosis and thrombosis. J Atheroscler Thromb. 2007;14 (5):261–265.
    31.    Koska J, Stefan N, Permana P A et al. Increased fat accumulation in liver may link insulin resistance with subcutaneous abdominal adipocyte enlargement, visceral adiposity, and hypoadiponectinemia in obese individuals. Am J Clin Nutr. 2008;87 (2):295–302.
    32.    Warne JP. Tumour necrosis factor alpha: a key regulator of adipose tissue mass. J Endocrinol. 2003;177 (3):351–355.
    33.    Juge-Aubry CE, Henrichot E, Meier CA et al. Adipose tissue: a regulator of inflammation. Best Pract Res Clin Endocrinol Metab. 2005;19 (4):547–566.
    34.    Насонов Е. Л., Самсонов М. Ю., Беленков Ю. Н., Фукс Д. Н. Иммунопатология застойной сердечной недостаточности, роль цитокинов. Кардиология. 1999;39 (3):66–73.
    35.    Насонов Е. Л., Самсонов М. Ю. Новые аспекты патогенеза сердечной недостаточности: роль фактора некроза опухоли. Журнал Сердечная Недостаточность. 2000;1 (4):139–143.
    36.    Altman J. Weight in the balance. Neuroendocrinology. 2002;76 (3):131–136.
    37.    Harada T, Nakahara T, Yasuhara D et al. Obestatin, acyl ghrelin, and des-acyl ghrelin responses to an oral glucose tolerance test in the restricting type of anorexia nervosa. Biol Psychiatry. 2008;63 (2):245–247.
    38.    Агаджанян Н. А., Власова И. Г., Ермакова Н. В., Торшин В. И. Основы физиологии человека. Под ред. Агаджаняна Н. А. – М.: Российский университет дружбы народов, 2001. – 408 с.
    39.    Otto B, Cuntz U, Otto C et al. Peptide YY release in anorectic patients after liquid meal. Appetite. 2007;48 (3):301–304.
    40.    Арутюнов Г. П. Кахексия у больных с хронической сердечной недостаточностью. Каков масштаб проблемы? Что мы знаем и что нам делать? Сердечная недостаточность. 2001;2 (3):123–128.
    41.    Старкова Н. Т., Летова Е. К. Генерализованная липодистрофия в клинической практике. – М.: Медицина, 2001. – 240c.
    42.    Otake H, Shite J, Shinke T et al. Relation between plasma adiponectin, High-sensitivity c-reactive protein, And coronary plaque components in patients with acute coronary syndrome. Am J Cardiol. 2008;101 (1):1–7.
    43.    Madsen E L, Rissanen A, Bruun J M et al. Weight loss larger than 10 % is needed for general improvement of levels of circulating adiponectin and markers of inflammation in obese subjects: a 3‑year weight loss study. Eur J Endocrinol. 2008;158 (2):179–187.
    44.    Halabi S, Ou S-S, Vogelzang NJ, Small EJ. Inverse correlation between body mass and clinical outcomes in men with advanced castration-reccurent prostate cancer. Cancer. 2007;110 (7):1478–1484.
    45.    Van Elburg AA, Kas MJ, Hillebrand JJ et al. The impact of hyperactivity and leptin on recovery from anorexia nervosa. J Neural Transm. 2007;114 (9):1233–1237.
    46.    Lucas AR, Beard CM, O’Fallon WM, Kurland LT. 50‑year trends in the incidence of anorexia nervosa in Rochester, Minn.: a population-based study. Am J Psychiatry. 1991;148 (7):917–922.
    47.    Steinberger J, Kelly AS. Cardiovascular risk at the extremes of body composition. J Pediatr. 2006;149 (6):739–740.
    48.    Nergardh R, Ammar A, Brodin U. Neuropeptide Y facilitates activity-based-anorexia. Psychoneuroendocrinology. 2007;32 (5):493–502.
    49.    Germain N, Galusca B, Roux CW. Constitutional thinness and lean anorexia nervosa display opposite concentrations of peptide YY, glucagon-like peptide-1, greline and leptin. Am J Clin Nutr. 2007;85 (4):967–971.
    50.    Ольбинская Л. И. Игнатенко С. Б. Роль цитокиновой агрессии в патогенезе синдрома сердечной кахексии у больных с хронической сердечной недостаточностью. Сердечная недостаточность. 2001;2 (3):132–134.
    51.    Anker SD, Ponikowski P, Varney S et al. Wasting as independent risk factor for mortality in chronic heart failure. Lancet. 1997;349 (9058):1050–1053.
    52.    Костюкевич О. И., Хадышьян Г. Г. Коррекция системного воспаления методом нутритивной поддержки у пациентов с ХСН III–IV ФК. Журнал Сердечная недостаточность, 2005;6 (5);186–190.
    53.    McEntegart MB, Awede B, Petrie MC et al. Increase in serum adiponectin concentration in patients with heart failure and cachexia: relationship with leptin, other cytokines, and B-type natriuretic peptide. Eur Heart J. 2007;28 (7):829–835.
    54.    Filippatos G, Tsilias K, Baltopoulos G, Anthopoulos L. Serum leptin concentration in heart failure patients: does the literature reflect reality? Eur Heart J. 2000;21 (4):334–335.
    55.    El-Bindary EM, Darwish AZ. New biochemical markers in chronic heart failure. East Mediterr Health J. 2001;7 (4–5):697–706.
    56.    Doehner W, Pflaum CD, Rauchhaus M et al. Leptin, Insulin sensitivity and growth hormone binding protein in chronic heart failure with and without cardiac cachexia. Eur J Endocrinol. 2001;145 (6):727–735.

To access this material please log in or register

Register Authorize
Ru En